Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652478 · ClinicalTrials.gov registry record · Phase 2
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
A Phase 2 study of Healthy Volunteer and Weight Gain, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05652478 is a Phase 2 study of Healthy Volunteer and Weight Gain that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05652478, a Phase 2 study of Healthy Volunteer and Weight Gain, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF). Eligibility: Healthy people aged 18 to 55. Design: Participants will be screened. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function. Participants will have 2 inpatient stays at the clinic. Each stay will be for 11 nights, with a 3-week break between. Both DTG and TAF are gel caps swallowed once per day by mouth. Participants will take 1 drug for 8 days during each stay. Participants will have tests to see how their body uses energy: They will spend 23 continuous hours in a special room that measures how much oxygen they breathe in and how much carbon dioxide they breathe out. They will do this a total of 6 times. They will have a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. They will lie on a table. Electrodes will be placed on their hands and feet to measure body fat and lean body mass. They will stand still on a platform for about 30 seconds. High-resolution laser cameras will scan their bodies.
Conditions Studied
Interventions
- DRUG Tenofovir alafenamide
- DRUG Dolutegravir
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05652478
The ClinicalTrials.gov registry entry for NCT05652478 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (40% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir alafenamide is the first listed.
NCT05652478 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05652478 about?
NCT05652478 is a clinical study titled "Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers". Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understa...
What is the current status of trial NCT05652478?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-03-26. Estimated completion is 2030-01-31.
What conditions does trial NCT05652478 study?
This clinical trial studies the following conditions: Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer Inhibitors.
What interventions are being tested in trial NCT05652478?
The interventions under investigation include: Tenofovir alafenamide (DRUG), Dolutegravir (DRUG).
Who is sponsoring clinical trial NCT05652478?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05652478 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging of 18F-FDG Uptake
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging for 18F-NaF Uptake
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging for PSMA Expression
RECRUITING · Phase 2
-
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
COMPLETED · Phase 2
-
Healthy Volunteer Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.